NervGen Pharma Corp (NGEN) NPV

Sell:6.41 CADBuy:6.47 CAD0.44 CAD (7.33%)

Prices delayed by at least 15 minutes
Sell:6.41 CAD
Buy:6.47 CAD
Change:0.44 CAD (7.33%)
Deal now
Prices delayed by at least 15 minutes
Sell:6.41 CAD
Buy:6.47 CAD
Change:0.44 CAD (7.33%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.

Key people

Michael Kelly
President, Chief Executive Officer, Director
William J. Adams
Chief Financial Officer, Company Secretary
Daniel D. Mikol
Chief Medical Officer
Adam H. Rogers
Director
Gianni Ruffolo
Director
Brian Eric Bayley
Independent Director
Glenn A. Ives
Independent Director
Randall E. Kaye
Independent Director
Click to see more

Key facts

  • EPIC
    NGEN
  • Location
    Canada
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    CA64082X2032
  • Market cap
    CA$431.44m
  • Employees
    10
  • Shares in issue
    71.91m
  • Exchange
    TSX Venture Exchange
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.